» Articles » PMID: 16754927

When is Measuring Sensitivity and Specificity Sufficient to Evaluate a Diagnostic Test, and when Do We Need Randomized Trials?

Overview
Journal Ann Intern Med
Specialty General Medicine
Date 2006 Jun 7
PMID 16754927
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical value of using a new diagnostic test depends on whether it improves patient outcomes beyond the outcomes achieved using an old diagnostic test. When can studies of diagnostic test accuracy provide sufficient information to infer clinical value, and when do clinicians need to wait for results from randomized trials? The authors argue that accuracy studies suffice if a new diagnostic test is safer or more specific than, but of similar sensitivity to, an old test. However, if a new test is more sensitive than an old test, it leads to the detection of extra cases of disease. Results from treatment trials that enrolled only patients detected by the old test may not apply to these extra cases. Clinicians need to wait for results from randomized trials assessing treatment efficacy in cases detected by the new diagnostic test, unless they can be satisfied that the new test detects the same spectrum and subtype of disease as the old test or that treatment response is similar across the spectrum of disease.

Citing Articles

FIT as a Comparator for Evaluating the Effectiveness of New Non-invasive CRC Screening Test.

Senore C, Doubeni C, Guittet L Dig Dis Sci. 2024; .

PMID: 39560807 DOI: 10.1007/s10620-024-08718-w.


Designing Rigorous and Efficient Clinical Utility Studies for Early Detection Biomarkers.

Zheng Y, Wagner P, Singal A, Hanash S, Srivastava S, Huang Y Cancer Epidemiol Biomarkers Prev. 2024; 33(9):1150-1157.

PMID: 39223980 PMC: 11534000. DOI: 10.1158/1055-9965.EPI-23-1594.


Halo sign on temporal artery ultrasound versus temporal artery biopsy for giant cell arteritis.

Pouncey A, Yeldham G, Magan T, Lucenteforte E, Jaffer U, Virgili G Cochrane Database Syst Rev. 2024; 2:CD013199.

PMID: 38323659 PMC: 10848297. DOI: 10.1002/14651858.CD013199.pub2.


An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles.

Bresalier R, Senore C, Young G, Allison J, Benamouzig R, Benton S Gut. 2023; 72(10):1904-1918.

PMID: 37463757 PMC: 10511996. DOI: 10.1136/gutjnl-2023-329701.


The comparative interrupted time series design for assessment of diagnostic impact: methodological considerations and an example using point-of-care C-reactive protein testing.

Fanshawe T, Turner P, Gillespie M, Hayward G Diagn Progn Res. 2022; 6(1):3.

PMID: 35232491 PMC: 8888027. DOI: 10.1186/s41512-022-00118-w.